4SC Receives Milestone Payment from Research Collaboration with SKK
News Oct 15, 2012
4SC AG has announced that it has received a milestone payment from the Japanese pharmaceutical company Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya (SKK) under a previously-concluded research collaboration.
The milestone payment will go to 4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG specializing in the early-stage biopharmaceutical research and discovery of new drug substances.
Under the research collaboration, 4SC had contributed its know-how in the field of medicinal chemistry together with its expertise in computerized (in silico) screening and modelling for the rapid discovery, selection and optimization of new drug substances (hits and leads) to investigate new classes of substances for the potential therapy of metabolic diseases.
In its pharmaceutical research and development work, SKK has now achieved decisive progress with an optimized chemical compound resulting from this collaboration, which triggered the contractually-agreed milestone payment.
Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director of 4SC Discovery GmbH commented: 'We are very pleased to have received this milestone payment. This success further stresses our long-standing research expertise and the capabilities of our core technology for the discovery and optimization of new pharmaceutical compounds, a technology that we have been marketing more actively since early 2012 with the newly-launched 4SC Discovery. Our special thanks are due to our partner SKK for the fruitful and pleasant collaboration. We intend to use this and, in the future, similar ventures to further strengthen the business of both 4SC Discovery and the entire 4SC Group.'
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018